Joseph Douglas Lyon Sells 10,830 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Joseph Douglas Lyon sold 10,830 shares of the stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $26.00, for a total transaction of $281,580.00. Following the completion of the transaction, the insider now directly owns 7,314 shares of the company’s stock, valued at $190,164. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Joseph Douglas Lyon also recently made the following trade(s):

• On Thursday, April 4th, Joseph Douglas Lyon sold 5,443 shares of Corcept Therapeutics stock. The stock was sold at an average price of $26.00, for a total value of $141,518.00.
• On Monday, April 1st, Joseph Douglas Lyon sold 500 shares of Corcept Therapeutics stock. The shares were sold at an average price of $26.01, for a total value of $13,005.00.
• On Friday, February 16th, Joseph Douglas Lyon sold 1,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $26.00, for a total value of $26,000.00.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $24.48 on Wednesday. The business has a fifty day moving average price of $23.99 and a 200-day moving average price of $25.13. The company has a market capitalization of $2.55 billion, a PE ratio of 23.09 and a beta of 0.50. Corcept Therapeutics Incorporated has a 1-year low of $20.84 and a 1-year high of $34.28.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.04. The business had revenue of $146.80 million during the quarter, compared to analyst estimates of $141.19 million. Corcept Therapeutics had a net margin of 22.38% and a return on equity of 24.19%. Corcept Therapeutics’s revenue was up 38.9% compared to the same quarter last year. During the same period last year, the business earned $0.14 EPS. On average, sell-side analysts anticipate that Corcept Therapeutics Incorporated will post 0.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on CORT. Truist Financial upped their target price on shares of Corcept Therapeutics from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. HC Wainwright upped their price objective on shares of Corcept Therapeutics from $38.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Finally, StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 3rd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Corcept Therapeutics currently has a consensus rating of “Buy” and an average target price of $40.10.

Hedge Funds Weigh In On Corcept Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC boosted its stake in Corcept Therapeutics by 27.0% during the 4th quarter. Quadrant Capital Group LLC now owns 2,107 shares of the biotechnology company’s stock valued at $68,000 after purchasing an additional 448 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Corcept Therapeutics by 9.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,900 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 500 shares during the last quarter. Linden Thomas Advisory Services LLC boosted its position in shares of Corcept Therapeutics by 1.0% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 56,671 shares of the biotechnology company’s stock valued at $1,841,000 after buying an additional 555 shares during the last quarter. GAMMA Investing LLC increased its holdings in Corcept Therapeutics by 90.6% in the 1st quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock worth $31,000 after buying an additional 579 shares in the last quarter. Finally, Exchange Traded Concepts LLC raised its position in Corcept Therapeutics by 1.5% in the 4th quarter. Exchange Traded Concepts LLC now owns 44,448 shares of the biotechnology company’s stock worth $1,444,000 after buying an additional 641 shares during the last quarter. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.